bioRxivCancer BiologyPreprint
Multi-omic analysis of colorectal adenocarcinoma identifies a new subtype of myofibroblastic cancer-associated fibroblast expressing high level of B7-H3 and with poor prognosis value.
Maelle PicardiD, Arnaud GuilléiD, Pascal FinettiiD, Bernadette de RauglaudreiD, Nadiya BelfiliD, Lenaïg Maescam, David Jérémie BirnbaumiD, François BertucciiD, Émilie MamessieriD
Abstract
The high mortality rate of colorectal cancer (CRC) combined with the lack of non-toxic and efficient personalized treatments makes it urgent to develop new targeted therapies for this disease. B7-H3 appears to be a good target as it is overexpressed in tumor tissue compared to normal tissue. However, B7-H3 is a molecule with ambivalent functions and is expressed by different cell types. This complexity contributed to the delay in identifying cell subtypes that express B7-H3 and their potential role in colorectal oncogenesis. In this study, we used in silico bulk, single-cell, and spatial transcriptomic data to investigate the clinical and biological characteristics of tumors with high B7-H3 expression, the precise nature of cells expressing high level of B7-H3, and their temporal appearance during colorectal oncogenesis. We found that tumors with high B7-H3 expression corresponded to tumors with a predominant stroma composed mainly of fibroblasts. Among them, two subtypes of ecm-myCAF fibroblasts and pro-fibrotic pericytes specifically expressed high levels of B7-H3, the former being an independent factor for poor prognosis in CRC. Finally, by examining precancerous lesions, we report that fibroblast subtypes with high levels of B7-H3 appear early during oncogenesis, especially at the inflamed stage. We also shed light on the fact that anti-B7-H3 immunotherapies might therefore preferentially target cells from the microenvironment rather than the tumor cells. This is particularly important to understand the mode of action of the anti-B7-H3 antibody-drug conjugate, which is currently being tested in clinical trials in several solid tumors. HighlightsO_LIHigh level of B7-H3 expression is associated with poor prognosis in colorectal cancer C_LIO_LIB7-H3 is recurrently found expressed by two subtypes of cancer-associated fibroblasts (CAF): pro-fibrotic pericytes and ecm-myCAF C_LIO_LIB7-H3high ecm-myCAF subtype is an independent poor prognosis for survival C_LIO_LIB7-H3high ecm-myCAF is detectable in pre-cancerous inflamed colonic tissues C_LI
- organism: human
- assay: bulk RNA-seq
- assay: scRNA-seq
- assay: spatial transcriptomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: protein structure prediction
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- High-resolution integrative analysis allows characterization and spatial annotation of normal and cancer-associated colon fibroblasts
Emma W Viitala, Ella S. Salminen, … Saara Ollila·bioRxiv·Jul 29, 2025
- Comprehensive characterization of tumor microenvironment in colorectal cancer via histopathology-molecular analysis
- RBPMS as a novel marker for cancer-associated fibroblasts in distinguishing left and right colorectal cancer sidedness
Sahira Syamimi Ahmad Zawawi, Ahmad Aizat Abdul Aziz, … Marahaini Musa·bioRxiv·Aug 5, 2025
- Tumor-Antagonizing Fibroblasts Secrete Prolargin as Tumor Suppressor in Hepatocellular Carcinoma
B. Chiavarina, R. Ronca, … A. Turtoi·bioRxiv·Jan 4, 2021
- Consensus molecular subtyping of colorectal cancers is influenced by goblet cell content
Samuel A. Miller, Ahmed H. Ghobashi, Heather M. O’Hagan·Cancer GeneticsPeer-reviewed·Jan 26, 2021
- A fibroblast-rich transcriptomic axis reflects stromal remodeling within the CMS4 phenotype in colorectal cancer
Yuxi Zheng, Shuqiang Hao, Chonghe Jiang·bioRxiv·Sep 22, 2026